Solaris Resources (CVE:SLS) Cut to “Hold” at Maxim Group

Maxim Group cut shares of Solaris Resources (CVE:SLS) from a strong-buy rating to a hold rating in a research report report published on Tuesday,Zacks.com reports.

Solaris Resources Stock Down 2.7 %

SLS stock opened at C$6.15 on Tuesday. The business has a fifty day moving average price of C$6.15 and a 200 day moving average price of C$6.15. Solaris Resources has a fifty-two week low of C$1.38 and a fifty-two week high of C$7.09.

About Solaris Resources

SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.